US22663K1079
US22663K1079
Crinetics Pharmaceuticals, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 9.01B EUR | -- | -- | -- |
Enterprise Value | 7.85B EUR | -- | -- | -- |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -20.63x | -- | -- | -- |
Price to Sales | 213.8x | -- | -- | -- |
Price to Book | 7.54x | -- | -- | -- |
EV/Revenue | 186.25x | -- | -- | -- |
EV/EBITDA | -14.41x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -2.76% | -- | -- | -- |